Validation of a novel systematic social observation for assessing the social and built environment in neighborhoods surrounding community-based substance use programs
Publication date: 1 November 2026 Source: Drug and Alcohol Dependence, Volume 288 Author(s): Laura C. Chambers, Yu Li, Maxwell S. Krieger, Bennett Allen, Alex H. Kral, Jacqueline E. Goldman, Maria Mercedes Guzman Herrera, William C. Goedel, Brandon D.L. Marshall, Magdalena Cerdá
Validation of a novel systematic social observation for assessing the social and built environment in neighborhoods surrounding community-based substance use programs. // Drug and Alcohol Dependence. – URL: https://www.sciencedirect.com/science/article/pii/S0376871626003765?dgcid=rss_sd_all
Validation of a novel systematic social observation for assessing the social and built environment in neighborhoods surrounding community-based substance use programs. Drug and Alcohol Dependence. https://www.sciencedirect.com/science/article/pii/S0376871626003765?dgcid=rss_sd_all
“Validation of a novel systematic social observation for assessing the social and built environment in neighborhoods surrounding community-based substance use programs.” Drug and Alcohol Dependence.
@article{article43512,
title = {Validation of a novel systematic social observation for assessing the social and built environment in neighborhoods surrounding community-based substance use programs},
journal = {Drug and Alcohol Dependence},
url = {https://www.sciencedirect.com/science/article/pii/S0376871626003765?dgcid=rss_sd_all}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...